Blackrock Neurotech

Blackrock Neurotech’s mission is to provide innovative tools and neurotech expertise to translate technology into a novel, implantable clinical solutions that improve human lives.

Machinery Manufacturing Medical Device Neuroscience

$200M

Latest Funding

Venture Round

Latest Funding Stage

2024-04-30

Funding Date

130

Employees

United States

Location

Salt Lake City, Utah

City & State

Sales-Ready Summary

Blackrock Neurotech recently raised a $200M Venture Round and is actively hiring across multiple departments including Engineering, Research and Development, and IT, signaling potential expansion and new technology adoption. Companies offering engineering tools, R&D resources, or IT solutions should reach out to key decision-makers in those departments.

Key Contacts
Unlock Contact Information

Upgrade to access founder details

Upgrade Now
Open Positions
View Careers Page
Hiring For
Engineering Research and Development Internships Accounting/Finance Administrative Operations Management Marketing Regulatory/Quality Systems Information Technology Manufacturing
Unlock Tech Stack Data

Upgrade to access technology insights

Upgrade Now

Similar Startups

SkyMirr
SkyMirr  Logo

SkyMirr provides revolutionary RF technology for broadband wireless communication and medical equipment applications. It was founded in 2021 and is locate in Satellite Beach, Florida.

Gripp
Gripp Logo

Gripp Ag revolutionizes farm activity and equipment tracking with a simple yet effective QR code and mobile app that allows users to capture unrecorded events.

OrganOx
OrganOx  Logo

OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.

Stablepharma
Stablepharma Logo

Stablepharma’s technology platform, StablevaX™ converts existing approved vaccines, therapeutics and diagnostics into fridge free thermostable products that do not require refrigeration to preserve them, thereby addressing the global challenges of the cold chain. Stablepharma’s R&D team have identified up to 60 vaccine candidates that could be suitable for StablevaX™ technology.